戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ides induced in vivo after immunization with varicella vaccine.
2 ted rash after receiving the live attenuated varicella vaccine.
3 ed 60-75 years (a comparison group) received varicella vaccine.
4 lus influenzae serotype b (Hib) vaccine, and varicella vaccine.
5 ion for Hib vaccine, and $221.64 million for varicella vaccine.
6 n immunocompromised patient who received the varicella vaccine.
7 : PCV13, rotavirus vaccine, Hib vaccine, and varicella vaccine.
8 who received 2 doses compared with 1 dose of varicella vaccine.
9  rates, before and after 1 dose of Merck/Oka varicella vaccine.
10  rarely have disease triggered by receipt of varicella vaccine.
11 genic potential of individual strains in the varicella vaccine.
12  microL are likely to benefit from receiving varicella vaccine.
13 increased concern about the effectiveness of varicella vaccine.
14 respiratory distress 5 weeks after receiving varicella vaccine.
15 s need in control of live measles, mumps, or varicella vaccines.
16 administered measles, mumps, and rubella and varicella vaccines.
17 se of the currently marketed live attenuated varicella vaccine (3625 pfu) or of a partially heat-inac
18  22 controls (15.7%) had received 2 doses of varicella vaccine, 66 cases (93.0%) vs 117 controls (83.
19 n investigational Oka strain live attenuated varicella vaccine, a 38-year-old healthy white woman dev
20 e reports of adverse events in recipients of varicella vaccine, a rate of 67.5 reports per 100,000 do
21                                              Varicella vaccine administered under routine conditions
22                                        Thus, varicella vaccine, administered carefully with close fol
23                           Clinical trials of varicella vaccine administration to immunocompromised ch
24                         Efficacy of one-dose varicella vaccine against all varicella was 65.4% (57.2-
25 and rubella and measles, mumps, rubella, and varicella vaccines among children who are 1 year of age.
26  its licensure in 1995, the extensive use of varicella vaccine and close surveillance of the associat
27 given as either MMR or measles-mumps-rubella-varicella vaccine and collectively referred to as MMR va
28       The immunogenicity of heat-inactivated varicella vaccine and effects on VZV pathogenesis were e
29 f varicella vaccine who had 1 or > 1 dose of varicella vaccine and in those who did or did not have a
30 valent combined measles, mumps, rubella, and varicella vaccine and measles-mumps-rubella and varicell
31 V) was developed to increase the coverage of varicella vaccine and reduce the number of injections ch
32 cinated population after the introduction of varicella vaccine and to determine the number of prevent
33 ic assays and to eliminate confusion between varicella vaccine and varicella zoster immunoglobulin.
34  recommended adding a routine second dose of varicella vaccine and weighed economic projections as we
35  been reported since the introduction of the varicella vaccine, and a booster vaccination may be nece
36                  Humoral immune responses to varicella vaccine are best achieved when children with P
37  the reported adverse events associated with varicella vaccine are minor, and serious risks appear to
38  data on a group of individuals who received varicella vaccine as healthy young adults 10-26 years ag
39 the strain carried 15 of 42 (36%) recognized varicella vaccine-associated single-nucleotide polymorph
40 roup), or (2) MMR at dose one and monovalent varicella vaccine at dose two (MMR+V group), or (3) two
41 icella vaccine and measles-mumps-rubella and varicella vaccines at separate injection sites given at
42 ts show that the clinical attenuation of the varicella vaccine can be attributed to decreased replica
43 Here, we rationally design a live-attenuated varicella vaccine candidate, v7D.
44 n children with leukemia in remission by the Varicella Vaccine Collaborative Study.
45 In seven studies of the effectiveness of the varicella vaccine conducted since it was licensed, the e
46           Despite 29 breakthrough cases, the varicella vaccine conferred a high degree of protection
47                                      Current varicella vaccines consisting of the live-attenuated vOk
48 as associated with a 4.0% increase in 1-dose varicella vaccine coverage.
49                                              Varicella vaccine currently is recommended for children
50                            A live attenuated varicella vaccine, derived from the Oka strain of VZV ha
51    A previously healthy boy who had received varicella vaccine developed herpes zoster with meningiti
52 ed complications demonstrates that 1 dose of varicella vaccine does not prevent serious disease in al
53 ecommended that children routinely receive 2 varicella vaccine doses in place of the 1 dose previousl
54 ) recommended administering a second dose of varicella vaccine during outbreaks, supplementing the ro
55                                              Varicella vaccine effectiveness against all forms of dis
56                                              Varicella vaccine effectiveness was calculated among chi
57 occurrence of CVS or major birth defects and varicella vaccine exposure during pregnancy, although th
58 aricella syndrome or other birth defects and varicella vaccine exposure during pregnancy.
59 accine uptake for 2-dose MCV and single-dose varicella vaccine, focusing on timeliness.
60  vaccine policy recommendation of 2 doses of varicella vaccine for all school-aged children should be
61              After US licensure of the Merck varicella vaccine for immunocompetent persons on 17 Marc
62 ecommendations are conditionally in favor of varicella vaccine for those not on immunosuppressive the
63                                  Inactivated varicella vaccine given before hematopoietic-cell transp
64 erstanding of the safety and efficacy of the varicella vaccine has been achieved through these invest
65 a undeniably indicate that immunization with varicella vaccine has been and continues to be successfu
66 arding the impact that the widespread use of varicella vaccine has had on the epidemiology of varicel
67 n in the United States who have received the varicella vaccine has increased there have been several
68                           Although 1 dose of varicella vaccine has provided excellent protection, a h
69                                  One dose of varicella vaccine, however, elicits detectable immune re
70 tor pregnancy outcomes of women who received varicella vaccine (ie, VARIVAX) inadvertently while preg
71                                 Two doses of varicella vaccine improved the vaccine's effectiveness b
72                          Before licensure of varicella vaccine in 1995, varicella was a universal chi
73  We assessed the effectiveness of 2 doses of varicella vaccine in a case-control study by identifying
74                         This experience with varicella vaccine in BMT patients is the first evidence
75 rubella vaccine administered with or without varicella vaccine in both younger and older children.
76               On the basis of studies of the varicella vaccine in healthy and immunosuppressed childr
77                                              Varicella vaccine in immunocompromised children was clin
78 ertaken to develop guidelines for the use of varicella vaccine in immunocompromised children.
79              The effectiveness of 2 doses of varicella vaccine in the first 2.5 years after recommend
80                            Widespread use of varicella vaccine in the United States could enable dete
81                        Widespread use of the varicella vaccine in the United States has led to import
82 and compared immune responses to measles and varicella vaccines in both groups.
83  virus (VZV)-containing vaccine (hereafter, "varicella vaccine") in frail nursing homes residents nor
84 mong children aged 19-35 months, >=1 dose of varicella vaccine increased from 16.0% in 1996 to 89.2%
85                     Similarly, VZV-RCF after varicella vaccine increased with age in subjects aged <1
86                                The Oka/Merck varicella vaccine induces VZV immunity in elderly nursin
87 mended 2-dose childhood vaccine schedule for varicella vaccine is a priority.
88 The combination measles, mumps, rubella, and varicella vaccine is associated with a 2-fold increased
89                                     Although varicella vaccine is effective, its effectiveness decrea
90                             A second dose of varicella vaccine is expected to increase seroconversion
91 ant (SOT) patients using the live-attenuated varicella vaccine is generally contraindicated, leaving
92                                     Although varicella vaccine is given to clinically stable human im
93                                  The current varicella vaccine is highly attenuated in the skin and y
94                                              Varicella vaccine is highly effective as used in clinica
95                              Live attenuated varicella vaccine is recommended for healthy individuals
96                                              Varicella vaccine is recommended for pediatric patients
97                The licensed, live attenuated varicella vaccine is safe and immunogenic in HIV-infecte
98 icted that immunization with live attenuated varicella vaccine is unlikely to be deleterious to HIV-i
99       The duration of protection provided by varicella vaccines is unclear.
100  live [Oka/Merck]; Merck), a live attenuated varicella vaccine, is indicated for vaccination against
101 e varicella incidence has declined following varicella vaccine licensure, herpes zoster (HZ) cases ma
102 1 in every 5 children who receives 1 dose of varicella vaccine may develop varicella disease, also kn
103                                          The varicella vaccine may eventually reduce or eliminate her
104  of combination measles, mumps, rubella, and varicella vaccine (MMRV) licensed in the United States u
105 wo doses of a combined measles-mumps-rubella-varicella vaccine (MMRV), one live attenuated varicella
106  vaccine or a combined measles-mumps-rubella-varicella vaccine (MMRV).
107                          Because lyophilized varicella vaccine must be stored frozen at -15 degrees C
108                             A second dose of varicella vaccine, now recommended for all children, cou
109 uated after 1 and 2 doses of live attenuated varicella vaccine, Oka strain, in several studies.
110     Immunisation is possible with monovalent varicella vaccine or a combined measles-mumps-rubella-va
111 n-Hodgkin's or Hodgkin's lymphoma to receive varicella vaccine or no vaccine.
112 a in naive children administered one dose of varicella vaccine or two doses of MMRV.
113 ses of MMRV, one dose of MMR and one dose of varicella vaccine, or two doses of MMR, 42 days apart.
114 use of the combination measles-mumps-rubella-varicella vaccine over separate measles-mumps-rubella an
115 s (7.0%) vs 1 control (0.7%) did not receive varicella vaccine (P < .001).
116 ill require further study to clarify whether varicella vaccine plays a role.
117                                              Varicella vaccine preferably should be given to children
118                  Introduction of a universal varicella vaccine program for U.S. children in 1996 spar
119                                  One dose of varicella vaccine provided moderate protection (82%-85%)
120 served, suggests that a two-dose schedule of varicella vaccine provided optimum long-term protection
121                             A second dose of varicella vaccine raises response rates to 99% and was r
122  were stratified by age: less than 20 years (varicella vaccine recommended), 20 to 59 years (no vacci
123                         Although the role of varicella vaccine remained unproven in most serious adve
124                      We summarize studies of varicella vaccine's effectiveness for prevention of vari
125 n the United States, studies have shown that varicella vaccine's overall effectiveness ranges from 44
126 e prompted the recommendation for a two-dose varicella vaccine series.
127 ation Practices for a routine second dose of varicella vaccine should lead to better varicella diseas
128 ldren with asthma, in those who received the varicella vaccine soon after the measles, mumps, and rub
129                         The live, attenuated varicella vaccine strain (vOka) is the only licensed the
130                                 Although the varicella vaccine substantially decreases morbidity and
131         Pregnant women occasionally received varicella vaccine through confusion with varicella zoste
132                      Many studies have shown varicella vaccine to be highly effective.
133                            Administration of varicella vaccine to HIV-infected or uninfected individu
134                Since the introduction of the varicella vaccine to the routine immunization schedule,
135          This case documents transmission of varicella vaccine type virus from a healthy vaccinee to
136   Varicella surveillance challenges predated varicella vaccine US licensure in 1995.
137    Despite no change in the scheduled age of varicella vaccine, use of MMRV vaccine was associated wi
138 aricella vaccine (MMRV), one live attenuated varicella vaccine (V) dose given after one measles-mumps
139 ted the data on the safety of single-antigen varicella vaccine (VAR) and assessed the safety of combi
140 rash and hepatitis 3 weeks after receiving a varicella vaccine (VAR).
141                                              Varicella vaccine (Varivax, Merck) has been available in
142 ing on polymorphisms between live attenuated varicella vaccine virus and wild-type varicella-zoster v
143                          The live attenuated varicella vaccine virus exhibited the same pattern of sh
144                           A live, attenuated varicella vaccine (vOka) was generated by using the VZV
145                      The live attenuated Oka varicella vaccine (vOka), derived from clade 2 wild-type
146                                  One dose of varicella vaccine was 84.5% effective (median; range, 44
147 ing outbreaks of varicella, a second dose of varicella vaccine was added to the routine immunization
148                            A live attenuated varicella vaccine was approved for use in the United Sta
149 f vaccine type, measles, mumps, rubella, and varicella vaccine was associated with a 1.4-fold increas
150 ensure of the combined measles-mumps-rubella-varicella vaccine was completed, which allowed harmoniza
151                                    While the varicella vaccine was created with approaches establishe
152                            A live attenuated varicella vaccine was developed in 1974 and was approved
153            Heat-inactivated, live attenuated varicella vaccine was given within 30 days before transp
154        Under conditions of intense exposure, varicella vaccine was highly effective in preventing mod
155            When administered after exposure, varicella vaccine was highly effective in preventing or
156 mmunization of young children with 1 dose of varicella vaccine was recommended in the United States i
157                                              Varicella vaccine was safe, immunogenic, and effective i
158           To assess the effectiveness of the varicella vaccine, we conducted a case-control study wit
159                   Almost 48 million doses of varicella vaccine were distributed between 1995 and 2005
160 n the offspring of women who were exposed to varicella vaccine while pregnant.
161 rate of zoster in 511 leukemic recipients of varicella vaccine who had 1 or > 1 dose of varicella vac
162              Concomitantly, a version of the varicella vaccine with 10 times the titer was developed
163 v7D is a promising candidate as a safer live varicella vaccine with reduced risk of vaccine-related c

 
Page Top